secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001104659-24-077372
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Carisma terminates Novartis manufacturing deal for CT-0508; pays $4M fee, suspends Phase 1 enrollment
--------------------------------------------------------------------------------

- Terminated Manufacturing and Supply Agreement with Novartis for CT-0508; effective July 31, 2024.
- Will pay $4.0M termination fee to Novartis in Q3 2024, with potential credit if Substitute Product transferred by Dec 31, 2024.
- Suspends enrollment of new patients in Phase 1 trial for CT-0508 to focus ex vivo oncology on follow-on candidate CT-0525.
- Revised operating plan narrows pipeline, prioritizing CT-0525 over CT-0508.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924077372/0001104659-24-077372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924077372/tm2418685d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-077372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer